AbbVie’s MAVIRET Gains EU Nod for Acute Hepatitis C Treatment — Enanta Pharmaceuticals, Inc.

Event summary

The European Commission approved AbbVie’s MAVIRET (glecaprevir/pibrentasvir) for acute hepatitis C virus (HCV) infection in adults and children aged 3+.
MAVIRET is now the only EU-approved treatment for both acute and chronic HCV infections.
Approval was supported by Phase 3 study data showing 96.2% sustained virological response at 12 weeks post-treatment.
Enanta Pharmaceuticals, which discovered glecaprevir, stands to benefit from increased MAVIRET adoption.

The big picture

This approval solidifies MAVIRET’s position as a leading pangenotypic treatment for HCV, addressing an unmet need in early-stage infection. The expansion into acute HCV could drive broader adoption and strengthen AbbVie’s market leadership in antiviral therapies. For Enanta, this represents another milestone in its strategy of leveraging small-molecule drug discoveries to generate sustainable revenue streams.

What we're watching

Market Penetration: Whether AbbVie can leverage this approval to expand MAVIRET’s market share in Europe, particularly among acute HCV patients.
Royalty Revenue: How increased demand for MAVIRET will impact Enanta’s royalty income from its partnership with AbbVie.
Competitive Dynamics: The pace at which competitors develop alternative treatments for acute HCV, potentially challenging MAVIRET’s dominance.